We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
The Fulham Shore Plc | LSE:FUL | London | Ordinary Share | GB00B9F8VG44 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.05 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
26/10/2009 11:27 | Here I am waiting patiently for the offer price to dip below 3.00p, so that I can add a few more, and this insane person persists in buying sizeable wads at above that price - another 174k snapped up at 3.05p this morning. How inconsiderate is that? Annual figures released on 12 November last year, not much longer to wait. | ansc | |
19/10/2009 09:25 | Ansc, Not sure if it will bomb but it is going nowhere fast. Not sure if you were here when I had over 1,500,000 of these at an average of just over 8p. Sold out at an average of about 6p. Not regreted it as I have made more than I lost and much more. Moved the money to NOP sold out and into AFR. Mind you put some in UVEL as a means of the China play and not done well there. A few other indifferent shares but on the whole I have no regrets but still keep an eye on this just to see when it will actually start delivering. To think I once even got a divident from this company. Good Luck to the die hard holders .... but sometimes it pays to admit that you got it wrong and move on. If the company doesn't go under then in time it will deliver. The big question is can you do better some where else or do you hang on in hope that it's time has come. If we all know the answer we all will be basking in Barbados now instead of watching the computer screen trying to pick a share. | buggy | |
15/10/2009 12:09 | Why on earth did someone buy 197k this morning, haven't they heard that the 'experts' on this thread have forecast that this share is going to bomb?! #[:-)] | ansc | |
02/10/2009 08:43 | The way this share appears to be manipulated I really get the impression there is a hidden agenda for this stock, they certainly discourage you to buy by the rediculous spread then give you a tasty morsal occasionally to temp you to sell or am I just becoming paranoid ;-[ | gimeabreak | |
01/10/2009 22:55 | 200K shares were sold @ 2.6p on the plus market. | ameer | |
01/10/2009 21:26 | Given the opportunities arriving for biotech, they need to diversify and quickly... | yogro | |
01/10/2009 18:56 | Amazing. Down 8% on zero trades and just look at that barmy spread. You would have to be barmy to buy (or inside) | scruff1 | |
26/9/2009 03:42 | classic behaviour, mark my words this dud will go back down in the next two weeks as sure as eggs is eggs | yogro | |
25/9/2009 17:40 | Thanks ansc. The Market Makers (quite like your version though as they do make all the money) are always in control on AIM except when they get caught short - usually napping. FUL is one of those very frustrating shares in that you always think it is about to finally break out but never actually quite manages it. The recent changes have been encouraging and FUL seems to be becoming much more professional with it's external image. Perhaps the next news will finally give it the legs to stand up ! | bbd2 | |
24/9/2009 21:21 | Answered my own question - it is traded on PLUS. Here is the link to the trades: | bbd2 | |
24/9/2009 21:12 | ansc, is Ful traded on plus as I can't see that transaction anywhere | bbd2 | |
24/9/2009 17:41 | I've only just noticed (on Hems) the '?' transaction for 1.2mil x 3.0p recorded at 16.22 yesterday allegedly; it certainly wasn't there when I checked a couple of hours after the close of play yesterday. But then, the Money Makers can get away with whatever takes their fancy these days, the LSE always turn a blind eye. | ansc | |
24/9/2009 14:34 | I've been in for just over five years, mm, so am pretty familiar with 'patience' as far as FUL is concerned. Another two years ...... a mere doddle! With seemingly so few investors interested in the company, timing your buys of FUL is of the essence as the Money Makers appear only too happy to drop the price on occasion for no obvious reason - during the last eight months they've graciously allowed me to add six lots of 100k in the price range 1.95 - 2.40p; any price below 2.5p and I'll still be happy to take a few more off their hands! Roll on November. | ansc | |
24/9/2009 13:09 | ansc I bought 3 years ago and have added during the recession too. Outsourcing will help them enormously. Still think that there is another 2 year wait whilst they demonstrate what they are capable of. Patience needed that's all and it's the sort of company that remains pretty solid in these uncertain times so I'm happy to stay with it. Price will grow from here and I somehow doubt we will see the 2-2.5p level again which is where I bought more at. DYOR | mountain man | |
24/9/2009 10:41 | I agree wholeheartedly about the next figures, mm, but I've kidded myself with those kind of thoughts for the last couple of years! Still, having made FUL one of only three company shares I was prepared to buy (and have bought) during this recession, I'm more than pleased with the share price performance so far this year. Final figures should be released in around seven weeks time (hopefully). | ansc | |
24/9/2009 09:27 | ansc Next report should be interesting - my guess is that the recession may have done FUL no harm at all for the longer term. | mountain man | |
24/9/2009 08:21 | Dummy trades online this morning indicate the narrowest spread I've ever seen for FUL - 3.01/3.20p for 25k. Should one interpret this as an indication that the Money Makers are lacking stock? Maybe you're right, gimeabreak, perhaps this Cinderella is, at long last, stirring ..... %[:-)] | ansc | |
23/9/2009 20:53 | That's what I like to see, another keen (or senseless!) FUL investor like myself - a 200k 'buy' marked late [16.26] @ 3.10p. I wonder what reaction (any?) we will get from the Money Makers first thing tomorrow ..... | ansc | |
23/9/2009 13:43 | Hello ansac, Something stirs. lol | gimeabreak | |
22/9/2009 11:32 | UPDATE: Cowen Healthcare Working On Three European Deals By Jason Douglas (of DOW JONES NEWSWIRES) - 18/09/09 Cowen Healthcare Royalty Partners, a U.S. healthcare investor, Friday said it is working on three major deals with pharmaceutical companies in Europe. Managing Director Greg Brown told Dow Jones Newswires each of the deals is worth in excess of $100 million. Cowen is a U.S. private equity firm that specializes in royalty-sharing, a type of financing whereby drugmakers sell a portion of the royalties from product sales for an immediate lump sum. These deals are typically an attractive way for small drug developers to get cash without tapping shareholders or borrowing, but Brown said two of the three European deals are with much bigger companies. He said he expects these two deals to complete by the year-end or early 2010. In the third deal, Cowen is proposing providing financing for the acquisition of a suite of products by a drugmaker, Brown said. He declined to name any of the parties involved in the three deals, citing confidential agreements. The money for the three deals will come partly from a new co-investment fund Cowen established with one of its key investors, worth in excess of $250 million. Brown said the types of financing Cowen specializes in are becoming more attractive to bigger drug companies because money isn't as cheap as it once was. Companies are keeping a closer eye on how they are spending their money and are increasingly looking to bring in outside capital to spread the risk, he said. "Capital efficiency had grown lax when the world was awash with liquidity and money was cheap," Brown said. Earlier this week, Cowen said two U.K. pharmaceutical executives are members of new strategic advisory board tasked with sounding out investment opportunities globally and carrying out due diligence. Frank Armstrong, chief executive of Fulcrum Pharma PLC (FUL.LN), and Michael Carter, a partner at venture capital group SV Life Sciences, have joined the advisory board. Cowen's recent deals included the purchase of a royalty stream from Canada's Aeterna Zentaris Inc. (AEZS) for the in-vitro fertilization drug Cetrotide for $52.5 million, and its deal for U.S. royalties from the cholesterol-lowering drug Fenoglide from Denmark's LifeCycle Pharma A/S (LCP.KO) worth up to $105 million. | ansc | |
09/8/2009 20:34 | I see it went 2.5p to 8p since March.. No doubt you got in, in March you jammy git! | bobp | |
22/7/2009 03:15 | bob p btw as a certified Uranian you may be interested in Forte energy | yogro | |
22/7/2009 03:13 | plenty of those left in your Uranian rump, | yogro | |
21/7/2009 11:07 | thats so old it was written using a feather :-) | bobp |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions